Author's response to reviews

Title: FOXP1 inhibits cell growth and reduces tumorigenicity of neuroblastoma

Authors:

Sandra Ackermann (sandra.ackermann@uk-koeln.de)
Hayriye Kocak (hayriye.kocak@web.de)
Barbara Hero (barbara.hero@uk-koeln.de)
Volker Ehemann (Volker.Ehemann@med.uni-heidelberg.de)
Yvonne Kahlert (yvonne.kahlert@uk-koeln.de)
André Oberthür (andre.oberthuer@uk-koeln.de)
Frederik Roels (frederik.roels@uk-koeln.de)
Jessica Theißen (jessica.theissen@uk-koeln.de)
Margarete Odenthal (m.odenthal@uni-koeln.de)
Frank Berthold (frank.berthold@uk-koeln.de)
Matthias Fischer (matthias.fischer@uk-koeln.de)

Version: 4
Date: 8 October 2014

Author's response to reviews: see over
Dear Dr. Rao,

thank you for giving us the opportunity to re-submit our manuscript “FOXP1 inhibits cell growth and reduces tumorigenicity of neuroblastoma” (MS: 59089541316238) to BMC Cancer. We appreciate the editor’s comments and have addressed the issues raised as indicated below and in the revised version of our manuscript.

1. We obtained ethics committee approvals for the use of tumor samples for the purposes of our study and informed consent from all patients. The following information has been added to the methods section of the manuscript: “All patients were registered in respective clinical trials with informed consent (NB2004, 04-049; NB97, 9764; ethical committee of the Medical Faculty of the University of Cologne).”

2. We added the two missing legends for additional files 1 (Table 1) and 2 (Table 2).

Thank you very much for your kind consideration of our work. I hope that the revised manuscript is now acceptable for publication in BMC Cancer.

We look forward to hearing from you.

Sincerely,

Sandra Ackermann, Ph.D.
University Children’s Hospital of Cologne
Department of Pediatric Oncology
E-mail: sandra.ackermann@uk-koeln.de

Cologne, 08-10-2014